Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
EGFR Non-Small Cell Lung Cancer Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The egfr non-small cell lung cancer market size has demonstrated robust growth in recent years. It is anticipated to increase from $9.34 billion in 2025 to $10.07 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. The expansion witnessed in the past can be attributed to the rising prevalence of non-small cell lung cancer, advancements in molecular diagnostics, heightened awareness of egfr mutation testing, the proliferation of oncology specialty centers, and the enhanced availability of targeted therapies.
The egfr non-small cell lung cancer market is expected to experience significant expansion in the next few years. It is projected to achieve a size of $13.74 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.1%. This anticipated growth during the forecast period can be attributed to several factors, such as the increasing pipeline of next-generation egfr inhibitors, the rising adoption of precision oncology methods, the broader implementation of biomarker-driven treatment models, the growing integration of real-world evidence into oncology care, and a heightened focus on patient-centric cancer management. Major developments expected in the forecast period include the increasing uptake of targeted egfr therapies, a rise in the use of companion diagnostic testing, a greater emphasis on personalized treatment pathways, the expansion of combination therapy approaches, and enhanced integration of multidisciplinary cancer care.
Get A Free Sample Report With In-Depth Market Insights:
EGFR Non-Small Cell Lung Cancer Market Expansion Drivers: What’s Shaping Future Growth?
The epidermal growth factor receptor (EGFR) non-small cell lung cancer market is expected to expand going forward, driven by the escalating focus on personalized medicine approaches. Personalized medicine represents a medical strategy that customizes prevention, diagnosis, and treatment based on an individual’s genetic, environmental, and lifestyle characteristics. These personalized medicine approaches are gaining traction due to enhanced accessibility of genetic and molecular profiling, which facilitates the precise identification of disease-specific targets and allows for tailored treatments to improve patient outcomes. Within the context of epidermal growth factor receptor (EGFR) non-small cell lung cancer, personalized medicine supports by detecting specific EGFR mutations in patients, thereby enabling doctors to prescribe targeted therapies that optimize effectiveness while minimizing side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, stated that the FDA authorized 16 new personalized therapies for patients with rare diseases in 2023, marking a substantial increase from the six approvals recorded in 2022. Consequently, the increasing emphasis on personalized medicine approaches is propelling the growth of the epidermal growth factor receptor (EGFR) non-small cell lung cancer market.
EGFR Non-Small Cell Lung Cancer Market Segment Breakdown: Which Categories Lead On Revenue?
The egfr non-small cell lung cancer market covered in this report is segmented –
1) By Drug Type: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies; Late Phase
2) By Mutation Type: Exon 19 Deletions; Exon 21 L858R Substitution Mutations; Exon 20 Insertion Mutations; Other Mutation Types
3) By Treatment Type: Monotherapy; Combination Therapy
4) By Route of Administration: Oral; Intravenous
5) By End User: Hospitals; Specialty Oncology Centers; Cancer Research Institutes; Academic Institutes; Other End Users
Subsegments:
1) By Tyrosine Kinase Inhibitors: First Generation Tyrosine Kinase Inhibitors; Second Generation Tyrosine Kinase Inhibitors; Third Generation Tyrosine Kinase Inhibitors
2) By Monoclonal Antibodies: Anti Epidermal Growth Factor Receptor Monoclonal Antibodies; Dual Target Monoclonal Antibodies; Antibody Drug Conjugates
3) By Late Phase: Patritumab Deruxtecan; Other Late Phase Pipeline Therapies
EGFR Non-Small Cell Lung Cancer Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market are concentrating on developing innovative products, such as antibody drug conjugates, to enhance treatment effectiveness and minimize systemic adverse reactions compared to conventional chemotherapy. An antibody-drug conjugate (ADC) functions by connecting a cancer-targeting antibody to a potent drug, enabling the medication to be delivered directly to tumor cells while sparing healthy cells. For instance, in June 2025, AstraZeneca Plc, a UK-based biopharmaceutical company, announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received approval in the U.S. for treating adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have previously undergone EGFR-targeted therapy and platinum-based chemotherapy. This indication was granted accelerated approval based on the observed objective response rate (ORR) and duration of response (DoR), with continued approval contingent upon the confirmation of clinical benefit in a subsequent trial. The U.S. FDA extended this approval following Priority Review and Breakthrough Therapy Designation. The decision was further supported by a subgroup analysis from the TROPION-Lung05 Phase II trial and additional evidence from the TROPION-Lung01 Phase III trial.
EGFR Non-Small Cell Lung Cancer Market Industry Leaders And Competitive Landscape
Major companies operating in the egfr non-small cell lung cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Pfizer Inc., AstraZeneca Plc, Bayer AG, Eli Lilly and Company, Takeda Pharmaceuticals Company Ltd., Boehringer Ingelheim Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Taiho Pharmaceutical Co. Ltd., Jiangsu Hansoh Pharmaceutical Co. Ltd., Betta Pharmaceuticals Co. Ltd., ShanghAI Allist Pharmaceuticals Co. Ltd., Oric Pharmaceuticals Inc., Black Diamond Therapeutics Inc., G1 Therapeutics Inc., Dizal Pharmaceutical, ArriVent BioPharma Inc., and Cullinan Therapeutics Inc.
View The Full EGFR Non-Small Cell Lung Cancer Market Report:
EGFR Non-Small Cell Lung Cancer Market Regional Analysis And Top Geography
North America was the largest region in the epidermal growth factor receptor (EGFR) non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egfr non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
